real-time news and commentary for investors
Monday, Jan 7
The return of $10B-plus drug deals may be here as pharmaceutical companies appear to be gearing...
The return of $10B-plus drug deals may be here as pharmaceutical companies appear to be gearing up to start buying again. Five of the largest U.S. drug makers have spent the last several years building up their cash positions in anticipation of expiring patents. Now, with nearly $70B in cash equivalents at their disposal, all eyes are on JPMorgan’s annual health-care conference in San Francisco, where the big drug makers will likely be on the hunt for assets to fill revenue holes left by expired patents.